Introduction
============

The progression of prostate cancer differs between individuals, with some patients dying of metastatic cancer within only a few months of diagnosis, whereas in others it may be years after diagnosis or not at all. At present, serum prostate-specific antigen testing is the main method used to diagnose prostate cancer in clinical practice.[@b1-ott-8-3507] However, elevated serum prostate-specific antigen levels can also reflect pathological changes in other systems, so this test has poor specificity for prostate cancer. There is also no test presently available to predict the aggressiveness of the disease.[@b2-ott-8-3507],[@b3-ott-8-3507] The Gleason score is one of the most practical methods for evaluating a prostate cancer prognosis. However, errors can occur in the assessment itself or the interaction between them may also appear. Furthermore, inaccurate positioning of the needle during biopsy of the cancer tissue may result in unreliable sampling and scoring.[@b4-ott-8-3507] Therefore, existing tools and methods available cannot specifically test for, or accurately diagnose how aggressive the disease is, and thereby identify which patients would benefit from aggressive intervention or a more conservative approach. During 12 years of comparing observations between randomized clinical studies of prostate cancer localization and conservative observation, complete resection of the prostate did not significantly reduce the related death rate of prostate cancer patients.[@b5-ott-8-3507] New biomarkers are needed which can accurately and effectively evaluate the disease's progression in a patient with cancer. In this study, we will explore the clinical and practical significance of these biomarkers based on their cell cycle progression score of RNA, apparent biological genetic markers, and protein expression.

Development of prostate cancer is associated with methylation of DNA, and there is increasing evidence to suggest that methylation has the potential to improve sensitivity in the diagnosis of prostate cancer, and that DNA methylation can play a complementary role, or even replace the cell cycle progression score and immunohistochemical analysis, in this regard.[@b6-ott-8-3507],[@b7-ott-8-3507] The advantages of methylation testing include its robustness as a test for stable DNA and its low cost. However, as a clinical method for detecting the aggressiveness of the prostate cancer and its potential risk of death, its prognostic value is limited to primary stages instead of terminal points, in detecting its postsurgical biochemical recurrence. In one observational cohort study, *HSPB1* methylation was examined as a means to predict the death rate of patients with prostate cancer.[@b8-ott-8-3507] In our study, which focused on patients with localized prostate cancer and a Gleason score ≤7, in both the case group and control group, we searched for genes similar to *HSPB1* in order to explore whether methylation in any of the identified genes could be used as an index of survival prognosis in patients with prostate cancer. The study included two phases, ie, an evaluation of methylation levels of *WNT5a*, *CTNNB1*, *SPARC*, *EPB41L3*, *PITX2*, *TOP2a*, *CDC20*, *LINE1*, *miR-23b*, and *TPM4* in samples of frozen prostate cancer and benign prostatic hyperplasia. The aforementioned genes, in particular *PITX2I*, were identified through a literature review as being abnormally expressed or methylated in prostate cancer, and a number of studies indicated their ability to predict biochemical recurrence in patients with prostate cancer. We investigated the expression of *PTIX2* by real-time polymerase chain reaction (PCR), and undertook further testing to explore whether the expression of this gene differed between those found in prostate cancer or in benign prostatic hyperplasia. Our hypothesis was that there would be significant differences in methylation levels between the case group and control group and that untreated patients with prostate cancer with a low Gleason score may still have a high risk of mortality.

Materials and methods
=====================

Specimens and patient information
---------------------------------

Prostate tissue specimens were taken from patients with either prostate cancer or benign prostatic hyperplasia. DNA from 20 cases were extracted from frozen tissue (ten cases with prostatic cancer, and ten cases with benign prostatic hyperplasia), and applied in the first stage of this study. In the second stage of the study, 367 DNA samples was extracted from prostate tissue specimens of prostate cancer patients by formalin-fixed transurethral resection. These patients had presented typical clinical symptoms and did not receive any surgery or radiation therapy for half a year. The primary endpoint in the study was death from prostatic cancer of which the relevant information was obtained from hospital medical records. Of the 367 samples, 275 of these patients had a Gleason grade of ≤7 points, with 229 of these cases being still alive at the time or had died of other systematic diseases, leaving 46 cases with death specially due to prostatic cancer, which were used as our case group. Ninety of the 229 cases who were either still alive or had died from other systematic diseases were used as the control group. To make up the 90 patients in the control group, all patients who were still alive from the 367 cases were included, and the patients who died of other systematic diseases with the longest preliminary end point, decided by survival status, were chosen to make up the rest of the group. Survival was longer in the control group that in the case group. This study was approved by the ethics committee of Xinjiang Medical University, Xinjiang, People's Republic of China.

Methylation analysis
--------------------

We used an EpiTect bisulfite reagent kit (Qiagen NV, Venlo, the Netherlands) to transform 120--200 ng of DNA, and performed a PCR analysis of transformational DNA using a PyroMark PCR reagent kit (Qiagen) following the manufacturer's instructions. The transformational DNA was equal to 1,000 formalin-fixed, paraffin-embedded tissues or DNA from 400 frozen tissue cells. PyroMark Assay Design v 2.0.1.15 (Qiagen) was used to design the primers and avoid the overlapping of CpG positions on the basis of previous reports. The same 3--6 CpG positions for the targets of *PITX2*, *LINE1*, *TPM4*, and *SPARC* were chosen. In order to internally control the total bisulfite conversion, non-CpG cytosine was added when analyzed, with each PCR reaction containing 12.5 μL PCR main mixture, 2.5 μL Coral red, 2 μL DNA, 5 pmol primer, and double distilled water. The total volume was adjusted to 25 μL with a further 2.5 mM MgCl~2~ added to each reaction for the determination of *LINE1*. The mixture was circulated for 10 minutes at 95°C followed by 45 circulations at 94°C (30 seconds), and then underwent annealing for a further 10 minutes at the temperature of 72°C. The accuracy of amplification was confirmed by QIAxcel (Qiagen) and by pyrosequencing. A standard curve was drawn for the positive control (0.50% and 100% human gene methylation), and for the non-template control. Lastly, 200 ng of non-methylation and supermethylation DNA was used to obtain different ratios of DNA methylation and to evaluate the hydrogen sulfate conversion.

Statistical analysis
--------------------

The Mann--Whitney *U*-test was used to compare mean gene methylation levels between cancer tissues and benign prostate hyperplasia tissues. In this condition, univariate conditional logistic regression model at maximum conditional likelihood was used to analyze the methylation of each gene and its primary end point. Each kind of gene was analyzed separately, and *P*\<0.05 indicated a statistically significant difference. In order to reduce errors, we used the Benjamini--Hochberg method to keep the false positive rate at 5%.

Results
=======

DNA methylation in frozen tissues
---------------------------------

[Figure 1](#f1-ott-8-3507){ref-type="fig"} shows the methylation levels of the genes of interest in tissue from ten cases of prostate cancer and ten cases of benign prostatic hyperplasia. The methylation levels of *EPB41L3*, *SPARC*, *PITX2*, *WNT5a*, *miR-23b*, *TOP2a*, and *CDC20* genes in the cancer tissue were significantly higher than those in the benign prostatic hyperplasia; the most obvious difference between the two types of tissue was in *SPARC* (*P*=0.0002, area under the curve 1.0). Methylation levels for *CDC20*, *TOP2A*, and *CTNNB1* were relatively lower, \<5%, and this low level may be due to the reduced accuracy of pyrosequencing that is caused by measurement error. At the other end of the spectrum, methylation levels of *miR-23b* and *LINE1* were higher in all cancer detected samples. The maximum variation between cancer tissue and benign prostatic hyperplastic tissue can be as high as 10% to 20%.

DNA methylation in the case-control cohort
------------------------------------------

Gene methylation levels for *EPB41L3*, *SPARC*, *PITX2*, *WNT5a*, and *TPM4* were tested in 135 patients ([Figure 2](#f2-ott-8-3507){ref-type="fig"}), and the number of genes detected in each patient differed. [Table 1](#t1-ott-8-3507){ref-type="table"} shows the case number and the number of patients included in the analysis of each gene. [Table 1](#t1-ott-8-3507){ref-type="table"} shows that each gene methylation with a kind of layered distribution in case group and control group. The mean duration of follow-up was 7.8 years (median was 6.1 years) in the case group, and 15.3 years (interquartile range 6.8) in the control group. The methylation of each gene, univariate conditional logistic regression analysis of death from prostate cancer, and odds ratio (OD) are illustrated in [Table 1](#t1-ott-8-3507){ref-type="table"}. Before multiple testing adjustment, the methylation level of *PITX2* and *WNT5a* was evaluated to determine which of the two genes may be related to a patient's death due to prostate cancer (OD 1.56, 95% confidence interval 1.17--2.08 vs OD 1.28, 95% confidence interval 1.02--1.60). After adjusting for a 5% false positive rate, the methylation level of only *PITX2* remained significant for predicting the risk of death from prostate cancer (*P*=0.005). Since the methylation level of *PITX2* increased by 10%, the prostate cancer-related death events will increase by at least 1.56 times.

Discussion
==========

*PITX2* and methylation of *WNT5a* can be regarded as biological markers in the prognosis of prostate cancer, which evaluate Gleason score and the risk of death of patients with prostate cancer. Both *PITX2* and methylation of *WNT5a* react in the Wnt signaling pathway. *PITX2* is thought to be a transcription factor that is related to the beta-chain protein-dependent or independent pathways. *WNT5a* can be regarded as a typical ligand that can activate the beta-chain protein-dependent pathway.[@b9-ott-8-3507],[@b10-ott-8-3507] In this study, we did not deliberately choose the Wnt signaling pathway biological factors, but obtained them through a literature review at the initial stage of this study.

Supermethylation of *PITX2* has been confirmed to be a prognostic marker in prostate cancer, and can be used to assess for biochemical recurrence. It has also been found to be to the reduction in mRNA transcription.[@b11-ott-8-3507]--[@b14-ott-8-3507] Current studies related to *PITX2* and cancer biochemical recurrence rates use microarray and real-time PCR technology as the main methods to evaluate its methylation.[@b15-ott-8-3507] To our knowledge, this is the first study to confirm a direct correlation between methylation of *PITX2* and a Gleason score \<7 and the risk of death in patients with prostate cancer. As a prognostic biomarker, its dominance ratio is 1.56 (as an independent predictor, its dominance ratio is more than 1.5).

In this study, we use consecutive methylation data to define the value as either positive or negative. Further study is required to find the critical value of each gene and define them as positive or negative markers. Predictable biomarkers can be used in multivariate classifications, and their correlation to other genes can affect the clinical values. The critical values of multivariate classification are always the sum of the whole genome value, rather than the methylation level based at a singular gene level. In the present study, we also found that methylation of *SPARC* can be used to distinguish between benign prostate hyperplasia and prostatic cancer ([Figure 1](#f1-ott-8-3507){ref-type="fig"}), and there have been several reports suggesting that methylation of *SPARC* can also be a potential biomarker in diagnosis.[@b16-ott-8-3507]--[@b18-ott-8-3507] Further research with a larger sample size of prostate biopsy results are needed to confirm this.

The main limitation of this study is that we used formalin-fixed tissue, but we found that it is more suitable to use patients with prostate cancer who had never received any treatment in the last 20 years, although the preliminary conclusion is still needed to be confirmed by biopsy specimens evaluations. Cell cycle progression as the first validated scoring, and then confirmed by biopsy specimens, show that formalin-fixed tissue samples are suitable for the study of prostate cancer as prognostic biomarkers.[@b19-ott-8-3507],[@b20-ott-8-3507] A second limitation of this study is that the sample size was small, with only 45 cases of patients who had died as an outcome of prostate cancer and 90 cases as a control for comparison. However, the aim of this study was basically achieved, since we found at least one significant odds ratio of biomarker. The two obtained values as possible genetic biomarkers need to be further tested by a larger sample evaluation. By using molecular detection of body fluid such as a blood sample, compared with other invasive procedures such as biopsy, biomarkers are the ideal detection method. In some studies, aberrant gene methylation can be detected in blood and urine,[@b21-ott-8-3507],[@b22-ott-8-3507] so methylation of *PICX2* should also be able to be detected in body fluids.

In conclusion, patients with a low Gleason score are generally considered to be a low-risk population suitable for conservative treatment.[@b23-ott-8-3507]--[@b25-ott-8-3507] However, it is still very important to identify biological factors that can predict the aggressiveness of a tumor. In this study, we found high *PITX2* levels in patients who were given a low Gleason score but still went on to die from prostate cancer. Therefore, methylation of *PITX2* can be used as a potential biomarker to predict the risk of death in prostate cancer patients with lower Gleason scores. However, this needs to be further confirmed by a biopsy study from a larger sample size.
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![Methylation level of each gene in benign prostatic hyperplasia (gray) and prostatic cancer (black).\
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![Methylation level of each gene in benign prostatic hyperplasia (white color) and prostatic cancer (gray color).\
**Notes:** Each position of value boxplot represents the 5th, 25th, 50th, 75th, and 95th percentiles. The circles represent the statistical differences between the prostatic hyperplasia and prostatic cancer.](ott-8-3507Fig2){#f2-ott-8-3507}

###### 

Influence and importance of methylation of five genes

  Gene        OR (95% CI)         LR test   Adjusted *P*-value   Adjusted *P*-value[\*](#tfn1-ott-8-3507){ref-type="table-fn"}   Case number of failed analysis   Case number of successful analysis   Cases (n)
  ----------- ------------------- --------- -------------------- --------------------------------------------------------------- -------------------------------- ------------------------------------ -----------
  *PITX2*     1.56 (1.17--2.08)   10.85     9.9e^−0.4^           0.005                                                           11                               109                                  37
  *WNT5a*     1.28 (1.02--1.60)   5.02      0.025                0.063                                                           6                                120                                  40
  *SPARC*     1.10 (0.95--1.28)   1.53      0.216                0.359                                                           11                               112                                  38
  *EPB41L3*   1.04 (0.88--1.22)   0.18      0.674                0.755                                                           5                                124                                  42
  *TPM4*      0.97 (0.80--1.18)   0.10      0.755                0.755                                                           12                               109                                  37

**Note:**

After controlling for a 5% false positive rate by the Benjamini--Hochberg method.

**Abbreviations:** LR, likelihood ratio; OR, odds ratio; CI, confidence interval.
